Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research.
about
Vaccines for preventing malaria (blood-stage)Identification of minimal human MHC-restricted CD8+ T-cell epitopes within the Plasmodium falciparum circumsporozoite protein (CSP)Profiling the host response to malaria vaccination and malaria challengeVaccines against malariaMalaria vaccine: a future hope to curtail the global malaria burdenVaccines for malaria: how close are we?Structure of the Malaria Antigen AMA1 in Complex with a Growth-Inhibitory AntibodyCharacterisation of Plasmodium invasive organelles; an ookinete microneme proteomeMalaria vaccine based on self-assembling protein nanoparticlesHigh antibody titer against apical membrane antigen-1 is required to protect against malaria in the Aotus modelPlasmodium berghei histamine-releasing factor favours liver-stage development via inhibition of IL-6 production and associates with a severe outcome of diseaseImpact of RTS,S/AS02(A) and RTS,S/AS01(B) on genotypes of P. falciparum in adults participating in a malaria vaccine clinical trial.Multiple comparisons analysis of serological data from an area of low Plasmodium falciparum transmission.Safety and reactogenicity of an MSP-1 malaria vaccine candidate: a randomized phase Ib dose-escalation trial in Kenyan children.Safety and allele-specific immunogenicity of a malaria vaccine in Malian adults: results of a phase I randomized trial.Protection of rhesus monkeys by a DNA prime/poxvirus boost malaria vaccine depends on optimal DNA priming and inclusion of blood stage antigens.Safety and immunogenicity of an AMA-1 malaria vaccine in Malian adults: results of a phase 1 randomized controlled trialSafety and immunogenicity of a recombinant Plasmodium falciparum AMA1 malaria vaccine adjuvanted with Alhydrogel, Montanide ISA 720 or AS02.Blood stage malaria vaccine eliciting high antigen-specific antibody concentrations confers no protection to young children in Western Kenya.Phase 1/2a study of the malaria vaccine candidate apical membrane antigen-1 (AMA-1) administered in adjuvant system AS01B or AS02A.Immunological mechanisms underlying protection mediated by RTS,S: a review of the available data.Safety and immunogenicity of an AMA1 malaria vaccine in Malian children: results of a phase 1 randomized controlled trial.Enhancing protective immunity to malaria with a highly immunogenic virus-like particle vaccine.Successful sporozoite challenge model in human volunteers with Plasmodium vivax strain derived from human donorsImmunogenicity and protection of a recombinant human adenovirus serotype 35-based malaria vaccine against Plasmodium yoelii in mice.The relationship between RTS,S vaccine-induced antibodies, CD4⁺ T cell responses and protection against Plasmodium falciparum infection.Adenovirus particles that display the Plasmodium falciparum circumsporozoite protein NANP repeat induce sporozoite-neutralizing antibodies in miceExtended safety, immunogenicity and efficacy of a blood-stage malaria vaccine in malian children: 24-month follow-up of a randomized, double-blinded phase 2 trial.Malaria Vaccines: Moving Forward After Encouraging First Steps.A field trial to assess a blood-stage malaria vaccine.Ad35.CS.01-RTS,S/AS01 Heterologous Prime Boost Vaccine Efficacy against Sporozoite Challenge in Healthy Malaria-Naïve Adults.Murine immune responses to liver-stage antigen 1 protein FMP011, a malaria vaccine candidate, delivered with adjuvant AS01B or AS02AA novel chimeric Plasmodium vivax circumsporozoite protein induces biologically functional antibodies that recognize both VK210 and VK247 sporozoites.Priming with an adenovirus 35-circumsporozoite protein (CS) vaccine followed by RTS,S/AS01B boosting significantly improves immunogenicity to Plasmodium falciparum CS compared to that with either malaria vaccine alone.Tailoring subunit vaccine immunogenicity: maximizing antibody and T cell responses by using combinations of adenovirus, poxvirus and protein-adjuvant vaccines against Plasmodium falciparum MSP1.Malaria vaccines in development.DNA vaccines against tropical parasitic diseases.Particle-based platforms for malaria vaccines.Pre-erythrocytic malaria vaccines: towards greater efficacy.Molecular basis of allele-specific efficacy of a blood-stage malaria vaccine: vaccine development implications
P2860
Q21032518-70DE3A3E-6D24-4504-939E-C40711D6EC52Q21034050-ED6BFDCB-FC0A-4282-9B98-6E717C95C080Q26800494-E28FB6EC-A586-4B7A-B492-164C7B10BD51Q26995079-DBA4EA5D-5A8C-4F56-8BEA-01B02B191E31Q26996425-B9412C6C-8617-4751-931E-24D7628EDA40Q27024344-32E307FB-7C85-401D-939A-26DC5EC6248BQ27648686-D9487BB0-8930-445E-B904-2BFA482D4AFCQ27972689-647BF793-E7E8-4B8E-89D4-E358BE416121Q28268609-60F386E1-BF84-42DD-8D1A-3AEF6660D070Q28749979-BEBB89E3-2EA6-490A-900E-B87CD4C1A3D0Q30039017-6B9966BB-ABF1-4EA7-A2CD-A4A0A7544DFCQ30895708-F87ED2E5-F527-4FDC-BF10-499C40366F37Q31018004-1C97500D-C310-4D0E-A96C-A61E2072C9A7Q33264521-CB8E6780-4E32-4628-AD4C-052A8B94DF43Q33264523-03E7899F-A230-4B9A-94AC-0E805BD3A6EEQ33303670-39DFF5B5-0304-45B1-8FE9-65C50DC1ED7AQ33316023-22FA9E0A-0609-4F6C-AE4C-ADFB453ECA28Q33394245-80F2DA1D-806F-43DE-A693-4FDC4DD1948BQ33415066-4FC74F50-4865-4131-8E76-096032A55748Q33434412-C1867D33-3591-4360-B847-A8F581AA1D5AQ33521372-A487CB8C-72D2-406C-AE3D-88E553122FFFQ33530106-4C90A136-7DA6-4FBD-8257-9CA9DFD2B92BQ33577093-7B7A3E3E-F40D-44B2-876F-36654883017CQ33680757-9988BD1F-82B4-4F91-B27C-06A8F1EBA7AEQ34301004-760B1175-5783-4EBD-B555-92240BBFD9EDQ34684347-E5F4E6AC-129D-4512-96AE-F8F1797789E8Q34700810-14B69EB1-591D-4305-8ACC-1B6BD0EA073AQ35048336-CC27E07E-119F-47D5-918B-D1601B201DC5Q35619891-DB0999B0-9A58-4E7F-B126-A6F559A7F3C0Q35622737-DD8C678A-62D2-4AAE-8CE4-0E6FC31F478BQ35684141-7B4C6440-7AE5-49D2-A3E8-4CD8D31EC042Q35689159-B0D88054-D34A-4AAA-AA8B-0A1786D5F031Q35689495-060B54C3-7EF7-4EA6-B774-54A7AA94BD56Q35784197-A28CEF42-62A5-4B11-8193-F9E9F013AAD8Q36114395-6EA6F7D1-610F-4D26-B687-B8E7ABB24072Q36219634-41C8A138-94E7-44C7-BB20-29C3C7DF0ADEQ36238733-6D939C12-9FD3-4E2A-BC3B-7621647DD5ECQ36396040-2B635C78-49D6-4B4A-B39C-4E1519C234BAQ36403400-EC79F4E7-1B26-454D-BA36-B3A7983441E1Q36509831-7ABCFE4E-A44E-4F42-B8FF-D09B8003CAA9
P2860
Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research.
description
2005 nî lūn-bûn
@nan
2005 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի մարտին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
name
Towards an RTS,S-based, multi- ...... ed Army Institute of Research.
@ast
Towards an RTS,S-based, multi- ...... ed Army Institute of Research.
@en
Towards an RTS,S-based, multi- ...... ed Army Institute of Research.
@nl
type
label
Towards an RTS,S-based, multi- ...... ed Army Institute of Research.
@ast
Towards an RTS,S-based, multi- ...... ed Army Institute of Research.
@en
Towards an RTS,S-based, multi- ...... ed Army Institute of Research.
@nl
prefLabel
Towards an RTS,S-based, multi- ...... ed Army Institute of Research.
@ast
Towards an RTS,S-based, multi- ...... ed Army Institute of Research.
@en
Towards an RTS,S-based, multi- ...... ed Army Institute of Research.
@nl
P2093
P50
P1433
P1476
Towards an RTS,S-based, multi- ...... ed Army Institute of Research.
@en
P2093
Amanda Leach
B Ted Hall
Carter Diggs
Christian A Darko
Christian F Ockenhouse
Collette Hillier
D Gray Heppner
David E Lanar
Evelina Angov
James F Cummings
P304
P356
10.1016/J.VACCINE.2005.01.142
P407
P50
P577
2005-03-01T00:00:00Z